HPC HOLDINGS (01742) releases interim results, with a profit of SGD 31.342 million for the period, an increase of 4766.77% compared to the previous year.
HPC Holdings (01742) released its interim results for the six months ending on April 30, 2025.
HPC Holdings (01742) released its interim results for the six months ending on April 30, 2025. The revenue was SGD 118 million, an increase of 35.43% compared to the previous year; the net profit for the period was SGD 31.342 million, an increase of 4766.77% compared to the previous year; and the basic earnings per share was SGD 1.96 cents.
Related Articles

Bitcoin's Market Dynamics and the Evolving Crypto Landscape

Apeloa Pharmaceutical(000739.SZ): The application for the market approval of Tolterodine Succinate, a chemical raw material for pharmaceuticals, has been approved.

Wanbang Pharmaceutical Holding Group's subsidiary Shishanjianjia controlled-release tablets obtained ethical approval.
Bitcoin's Market Dynamics and the Evolving Crypto Landscape

Apeloa Pharmaceutical(000739.SZ): The application for the market approval of Tolterodine Succinate, a chemical raw material for pharmaceuticals, has been approved.

Wanbang Pharmaceutical Holding Group's subsidiary Shishanjianjia controlled-release tablets obtained ethical approval.

RECOMMEND

Trump Signals End to Trade Talks, Vows to Impose Tariffs Unilaterally Ahead of July 9 Deadline
30/06/2025

One License Unlocks HKD 23.4 Billion Surge: Unpacking Hong Kong’s Ambitions as a Global Virtual Asset Hub
30/06/2025

16 Companies Submit IPO Applications in One Day; Hong Kong IPO Fundraising Hits Three-Year High
30/06/2025